Indian pharma sector needs price hikes, site and IP transfers to tackle US tariff uncertainty: Report

A Systematix Research report indicates the Indian pharmaceutical industry is navigating uncertainty due to US tariffs, necessitating price increases, site transfers, and IP transfers. While raw material prices stabilize and companies explore new growth avenues, first quarter earnings were weak, with margin pressures in the US market. Firms cautiously evaluate inorganic growth and focus on OTC platforms amid these challenges.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ONbHWxd
via IFTTT